



INVESTING IN HEALTH PROGRAMS FOR SOCIETY:

The Role of Innovation and Impact Investing



Dr. Vladimir Cmiljanovic
- Founder, Swiss Rockets
- vladimir.cmiljanovic@swissrockets.com
swissrockets.com

Advancing Healthcare Through Innovation

We live in a crucial time for healthcare, where new challenges keep popping up, and many medical needs are still unmet. Swiss Rockets AG, founded in 2018, is at the forefront of biotech innovation, identifying, investing in, and cultivating groundbreaking solutions for some of the world's most pressing health concerns. As an umbrella company, Swiss Rockets oversees a portfolio of niche-leading biotech firms dedicated to developing transformative therapies.

Our subsidiaries, including Rocketvax, Torqur, and Torpedo Pharmaceuticals, focus on solutions for infectious diseases, cancer, and autoimmune disorders.

Rocketvax is working on an easy-to-administer, needle-free intranasal COVID-19 vaccine designed to offer long-lasting immunity.

Torqur is advancing novel therapies for actinic keratosis, prostate cancer, and head and neck cancer, improving efficacy and safety.

Torpedo Pharmaceuticals is using radioligand therapies to specifically target cancer cells.

These innovations highlight the potential of biotech investment in addressing crucial healthcare challenges.

Relevance for Current Health Concerns: Addressing Unmet Needs

The COVID-19 pandemic highlighted some serious weaknesses in our global healthcare system, making it clear that we must innovate urgently. With new variants still emerging, Rocketvax's intranasal vaccine is a game-changer in the fight against the disease.

On another front, cancer continues to be a leading cause of death around the globe, and

unfortunately, many treatments just don't cut it in terms of effectiveness and patient comfort. That's where Swiss Rockets' subsidiaries come in, working hard to create targeted, effective, and patient-friendly therapies that fill these gaps.

When we invest in healthcare innovation, we're not just enhancing patient outcomes; we're also easing the financial strain that comes with long-term illnesses. Preventive measures like Rocketvax's vaccine and Torqur's topical treatment for actinic keratosis are helping us shift from a reactive approach to a proactive one—cutting down on hospital visits, reducing healthcare costs, and ultimately improving quality of life. This strategy fits perfectly with a larger vision of making healthcare sustainable and accessible for everyone.

The Power of Direct Access to Founders and Leading Scientists

What sets Swiss Rockets apart for investors is our hands-on approach. Our leadership team, made up of biotech entrepreneurs, esteemed scientists, and industry experts, offers investors a front-row seat to our strategic plans and research developments. This level of transparency builds trust and makes sure that investments are in sync with groundbreaking science and real-world applications.

Family offices and private investors gain a lot from direct conversations with the founders and top researchers at Swiss Rockets, allowing them to make well-informed decisions. Unlike the usual investment routes, where multiple layers of mediators can create a gap between investors and innovators, Swiss Rockets emphasizes teamwork, ensuring that funding goes straight to driving scientific progress and delivering effective healthcare solutions.

High Potential for Investors Seeking Value Enhancements

Investing in biotech is a fantastic opportunity for family offices and private investors looking for solid financial returns and a chance to positively impact society. The healthcare sector is known for its resilience and rapid growth, fueled by a rising demand for innovative treatments.

By investing in biotech, investors not only create economic value but also contribute to social responsibility by tackling important health issues.

Family offices are crucial in fostering medical innovation, as they provide funding for research and support early-stage biotech companies. Swiss Rockets' diverse portfolio allows investors to tap into various therapeutic areas that show excellent market potential.

With advancements in precision medicine, cutting-edge immunotherapies, and next-generation vaccines paving the way, investing in biotech is a bright, forward-looking strategy for wealth management that promises a lasting impact on global health.

The Broader Impact: Economic Growth and Preventive Healthcare

Investing in healthcare innovation goes beyond just financial gains; it is vital in driving overall

economic growth. When populations are healthier, we see a boost in productivity, lower healthcare costs, and a more efficient workforce.

Preventive care options, like vaccines and early-stage cancer treatments, help ease the economic strain caused by chronic diseases, leading to significant savings for both healthcare systems and governments.

Moreover, access to the latest treatments shouldn't be restricted by where you live or your financial situation. At Swiss Rockets, we're dedicated to ensuring that groundbreaking therapies are available to everyone so that advancements in medicine can truly benefit society as a whole. By focusing on affordability and scalability, we strive to connect scientific breakthroughs with patients' real needs.

Family Offices and Private Investors as Drivers of Socially Responsible Investment

Family offices and private investors have a unique role in promoting socially responsible investments, especially in the healthcare sector. Unlike traditional venture capital firms that often chase quick profits, family offices can take a longer view, investing in projects that create meaningful, lasting change.

By backing biotech initiatives, these investors help foster the creation of life-saving therapies, boost medical research, and enhance preventive healthcare systems. This approach not only aligns their investment strategies with ethical and philanthropic goals but also underscores the vital role of health in sustainable development.

Shaping the Future of Healthcare Investments

The crossroads of healthcare innovation and investment opens up a unique chance to create both financial gains and social impact. Swiss Rockets AG stands as a prime example of how biotech entrepreneurship can tackle pressing health issues while providing investors with exciting growth opportunities. By putting money into health initiatives, family offices, and private investors can not only boost their portfolios but also contribute to meaningful advancements in global healthcare.

For those seeking impactful investments that generate significant returns while improving lives, biotech offers a future-proof solution. The question is not whether to invest in healthcare innovation but rather how soon one can take part in shaping the future of medicine.

